TransMedics Group (TMDX) Tops Q4 EPS by $2.23, provides guidance

TransMedics Group (NASDAQ: TMDX) reported Q4 EPS of $2.62, $2.23 better than the analyst estimate of $0.39. Revenue for the quarter came in at $160.8 million versus the consensus estimate of $155.98 million.

GUIDANCE:

TransMedics Group sees FY2026 revenue of $727-757 million, versus the consensus of $725 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Boeing wins $121 million Navy contract for P-8A upgrades
• Eledon Pharamceuticals (ELDN) PT Raised to $7 at Leerink